AU-17105

N/A

Report date: 2025/06/11 11:06:19
NME

Base Information

Drug NameAU-17105
Drug Alias Namedual A2aR checkpoint inhibitor/CD73 checkpoint inhibitor (Aurigene)dual A2aR/CD73 antagonists (Aurigene)AU-17105AU-17510
ClassificationSmall molecules
Mechanisms of Action5'-nucleotidase inhibitorsImmunostimulantsT lymphocytes stimulants +[5] 
Targets5'-nucleotidaseAdenosine A2a receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAurigene Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAurigene Oncology Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A